B

BMY

BMY

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
33%Bearish
Buy/Sell Ratio8% buys
BearishBullish
BMY Live QuoteReal-time
$58.34
$2.78(-4.55%)1M
Day Range$57.88 – $59.30
Open$59.19
Previous Close$59.56
Volume13.68M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$119.25B
P/E Ratio (TTM)12.9
Forward P/E9.0
EPS (TTM)$4.51
Price to Book5.2
Dividend Yield4.23%
Beta (Volatility)0.19
IndustryDRUG MANUFACTURERS - GENERAL
52-Week RangeCurrent: $58.34 (57%)
Low: $45.55High: $67.94
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$65.25-56.5% upside

Insider Buys

3

$412K

Insider Sales

6

$4.96M

Total Volume

$5.37M

9 transactions

Net Activity

$4.55M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
60CONFIDENCE

Sentiment Rating

Moderate Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Heavy distribution: sales represent 92% of total transaction value.
  • •Minor cluster buying: 2 unique insiders purchased shares.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
E
1

Elkins David V

EVP, CFO

0 buys2 sells

$4.50M total

M
2

Massacesi Cristian

EVP,Chief Med Offr,Head of Dev

0 buys1 sells

$403K total

H
3

Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

2 buys0 sells

$302K total

B
4

Boerner Christopher S.

CEO

1 buys0 sells

$110K total

H
5

Holzer Phil M

SVP, Controller

0 buys1 sells

$34K total

Trading History
BMY insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 9, 2026

2 months ago

Massacesi Cristian

EVP,Chief Med Offr,Head of Dev

EVP
Sell6.2K$64.57$403K

Aug 25, 2026

2 months ago

Holzer Phil M

SVP, Controller

SVP
Sell500$67.50$34K

Apr 1, 2026

7 months ago

Elkins David V

EVP, CFO

CFO
Sell30.0K$61.67$1.85M

Sep 2, 2025

14 months ago

Elkins David V

EVP, CFO

CFO
Sell56.0K$47.33$2.65M

Aug 2, 2025

15 months ago

Short Bartie Wendy

EVP, Corporate Affairs

EVP
Sell378$44.23$17K

May 9, 2025

18 months ago

Hickey Benjamin

Pres, RayzeBio Org.

President
Sell97$38.01$4K

Apr 25, 2025

19 months ago

Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

EVP
Buy4.3K$47.58$202K

Feb 20, 2025

21 months ago

Boerner Christopher S.

CEO

CEO
Buy2.0K$55.05$110K

Feb 14, 2025

21 months ago

Hirawat Samit

EVP,Chief Med.Offr.,Drug Dev.

EVP
Buy1.8K$54.84$100K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
BMY Buy Conviction8%
Industry Rank#0 of 569
Volume Contribution0.0%
Total Industry Activity$16.53B

BMY has an insider buy conviction of 8%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for BMY

Over the last 90 days, corporate insiders at BMY (BMY) engaged in a total of 9 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 6 were sales. The total volume of insider trading reached $5.37M.

The net insider activity for BMY shows a net selling bias of $4.55M. This activity represents a 8% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Elkins David V (EVP, CFO), who traded 56.0K shares valued at $2.65M on Sep 2, 2025.

Live Market News & Developments
Aggregated real-time headlines for BMY (BMY)
6 updates

Is Bristol-Myers Squibb (BMY) Fully Valued Following Its Hematology Data Update?

Yahoo Finance6h ago

Bristol-Myers Squibb (NYSE:BMY): Dividend Quality Screen Highlights Income Case and Sustainability Risk

ChartMillYesterday

Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes

Investor's Business Daily39d ago

Which Dates Could Move Bristol Myers Squibb Stock Most?

Yahoo FinanceYesterday

Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare.

Barron's8d ago

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors

MarketWatchYesterday

FAQs About BMY Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for BMY.

Based on SEC Form 4 disclosures, the Insider Confidence Score for BMY is currently 60/100, which reflects a moderate accumulation bias. This calculation accounts for a total of 3 purchases and 6 sales by company executives over the last 90 days.

The CEO Conviction Index for BMY is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.